share_log

Cantor Fitzgerald Reiterates Overweight on Spero Therapeutics

Cantor Fitzgerald Reiterates Overweight on Spero Therapeutics

康泰菲洛重申对spero therapeutics的超配评级
Benzinga ·  08/06 11:18

Cantor Fitzgerald analyst Louise Chen reiterates Spero Therapeutics (NASDAQ:SPRO) with a Overweight.

Cantor Fitzgerald分析师Louise Chen重申对Spero Therapeutics(纳斯达克:spero therapeutics)的超重评级。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发